NZ535531A - Compound and use in treatment - Google Patents

Compound and use in treatment

Info

Publication number
NZ535531A
NZ535531A NZ535531A NZ53553104A NZ535531A NZ 535531 A NZ535531 A NZ 535531A NZ 535531 A NZ535531 A NZ 535531A NZ 53553104 A NZ53553104 A NZ 53553104A NZ 535531 A NZ535531 A NZ 535531A
Authority
NZ
New Zealand
Prior art keywords
bph
preservatives
compound
alpha
treatment
Prior art date
Application number
NZ535531A
Other languages
English (en)
Inventor
Luciano Adorini
Enrico Colli
Original Assignee
Bioxell Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322395A external-priority patent/GB0322395D0/en
Priority claimed from GB0325598A external-priority patent/GB2407499B/en
Priority claimed from GB0416876A external-priority patent/GB0416876D0/en
Application filed by Bioxell Spa filed Critical Bioxell Spa
Publication of NZ535531A publication Critical patent/NZ535531A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NZ535531A 2003-09-24 2004-09-23 Compound and use in treatment NZ535531A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0322395A GB0322395D0 (en) 2003-09-24 2003-09-24 Methods for treating bladder dysfunction and related compounds and compositions
GB0325598A GB2407499B (en) 2003-11-03 2003-11-03 Vitamin D3 analogue for use in the treatment of BPH
GB0416876A GB0416876D0 (en) 2004-07-29 2004-07-29 Compound and use in treatment

Publications (1)

Publication Number Publication Date
NZ535531A true NZ535531A (en) 2006-03-31

Family

ID=34229055

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ535531A NZ535531A (en) 2003-09-24 2004-09-23 Compound and use in treatment

Country Status (12)

Country Link
EP (1) EP1673096A1 (fr)
JP (2) JP2007506699A (fr)
CN (1) CN100488511C (fr)
BE (1) BE1016292A3 (fr)
BR (1) BRPI0404050A (fr)
CH (1) CH698144B1 (fr)
EA (1) EA010240B1 (fr)
FR (1) FR2859910B1 (fr)
HK (1) HK1085373A1 (fr)
NL (1) NL1027109C2 (fr)
NZ (1) NZ535531A (fr)
WO (1) WO2005027923A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038611A1 (fr) * 2004-10-05 2006-04-13 Kissei Pharmaceutical Co., Ltd. Agent pour le traitement prophylactique ou thérapeutique des troubles de collecte de l'urine dans la vessie consécutifs à l'obstruction du canal urinaire inférieur
JPWO2006038619A1 (ja) * 2004-10-06 2008-05-15 キッセイ薬品工業株式会社 前立腺肥大症に対する手術療法への移行予防用医薬組成物
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
US20120164240A1 (en) 2010-12-22 2012-06-28 Audino David Lawrence Enriched a. blitoides compositions and uses thereof
US20170049834A1 (en) * 2015-08-18 2017-02-23 Golden Biotechnology Corporation Benign prostatic hyperplasia add-on therapy
FR3063906A1 (fr) * 2017-03-20 2018-09-21 Pierre Fabre Medicament Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
TW403735B (en) * 1995-11-22 2000-09-01 Hoffmann La Roche 25-hydroxy-16-ene-26, 27-bishomo-cholecalciferol
SG70009A1 (en) * 1996-05-23 2000-01-25 Hoffmann La Roche Vitamin d3 analogs
EP0981523B1 (fr) * 1997-05-16 2005-12-07 Woman & Infants Hospital Composes de vitamine d3 a ether cyclique et composes de 1alpha(oh)3-epi-vitamine d3, et utilisation desdits composes
US5872113A (en) * 1997-05-16 1999-02-16 Syntex (U.S.A.) Inc. Fluorinated vitamin D3 analogs
US6255501B1 (en) * 1999-04-26 2001-07-03 Hoffman-La Roche Inc. Process for preparing antiosteoporotic agents
WO2003034961A1 (fr) * 2001-10-23 2003-05-01 Euro-Celtique, S.A. Procedes et dispositif transdermique de terazosine
HUP0501186A2 (en) * 2001-12-03 2006-05-29 Novacea Pharmaceutical compositions comprising active vitamin d compounds

Also Published As

Publication number Publication date
EA010240B1 (ru) 2008-06-30
WO2005027923A1 (fr) 2005-03-31
JP2009035559A (ja) 2009-02-19
EA200401100A1 (ru) 2005-04-28
CH698144B1 (fr) 2009-05-29
NL1027109A1 (nl) 2005-03-29
HK1085373A1 (en) 2006-08-25
NL1027109C2 (nl) 2005-05-03
FR2859910B1 (fr) 2006-04-28
EP1673096A1 (fr) 2006-06-28
JP2007506699A (ja) 2007-03-22
BRPI0404050A (pt) 2005-06-14
CN100488511C (zh) 2009-05-20
CN1615891A (zh) 2005-05-18
BE1016292A3 (nl) 2006-07-04
FR2859910A1 (fr) 2005-03-25

Similar Documents

Publication Publication Date Title
AU2002327180A1 (en) Detection and therapy of vulnerable plaque with photodynamic compounds
ATE518540T1 (de) Beta-lactam verbindung enthaltende neurotherapeutische zusammensetzung
WO2003049702A3 (fr) Ligands de recepteur vanilloide et utilisation de ceux-ci dans des traitements
HK1079519A1 (en) Furyl compounds
CA2238993A1 (fr) Procedes de traitement du cancer de la prostate avec des antagonistes de la luliberine
NZ285159A (en) Treatment of benign prostatic hyperplasia, endometriosis, prostatic carcinoma and obesity by administration of droloxifene
HRP20050510A2 (en) Microbicide substances
PE20011167A1 (es) Composiciones farmaceuticas que comprenden un antagonista del alfa-adrenoreceptor y un antagonista muscarinico para el tratamiento de hiperplasia prostatica benigna
ATE427747T1 (de) Darreichungsformen enthaltend einen protonpumphemmer, einen nsaid und einen puffer
JP2005528401A5 (fr)
WO2001024763A3 (fr) Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques
WO2005016286A3 (fr) Modulateurs pyraziniques de recepteurs canabinoïdes
ECSP024382A (es) Inhibidores de proteasa de serina
WO2003045494A3 (fr) Therapies faisant appel a l'imiquimod
WO2005049000A3 (fr) Methodes et compositions pour le traitement des troubles du metabolisme
NZ535531A (en) Compound and use in treatment
AP2002002427A0 (en) Ppar compounds.
AU9678501A (en) Pharmaceutical solutions of modafinil compounds
EP1503748A4 (fr) Medicaments servant a attenuer la neurotoxicite induite par le taxane
DK1383516T3 (da) Indgivelse af et polysaccharid samtidig med et kemoterapeutisk middel til behandling af cancer
PE20040596A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan
UY26648A1 (es) Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada
ATE359248T1 (de) Rauch erzeugende zusammensetzung
RS50681B (sr) Kombinacija taksana i ciklin-zavisne kinaze
WO2002078633A3 (fr) Agent de traitement de symptomes d'irritation de la vessie accompagnes d'hyperplasie benigne de la prostate

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)